Literature DB >> 21964315

Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Andrei Soliakov1, Ian F Kelly, Jeremy H Lakey, Allan Watkinson.   

Abstract

An anthrax sub-unit vaccine, comprising recombinant Protective Antigen (rPA83) and aluminium hydroxide adjuvant (Alhydrogel®) is currently being developed. Here, a series of biophysical techniques have been applied to free and adjuvant bound antigen. Limited proteolysis and fluorescence identified no changes in rPA83 tertiary structure following binding to Alhydrogel and the bound rPA83 retained two structurally important calcium ions. For adsorbed rPA83, differential scanning calorimetry revealed a small reduction in unfolding temperature but a large decrease in unfolding enthalpy whilst urea unfolding demonstrated unchanged stability but a loss of co-operativity. Overall, these results demonstrate that interactions between rPA83 and Alhydrogel have a minimal effect on the folded protein structure and suggest that antigen destabilisation is not a primary mechanism of Alhydrogel adjuvancy. This study also shows that informative structural characterisation is possible for adjuvant bound sub-unit vaccines.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964315      PMCID: PMC3244517          DOI: 10.1016/j.ejpb.2011.09.009

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  38 in total

1.  Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors:  J Mogridge; M Mourez; R J Collier
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

Review 2.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

Review 3.  Probing protein structure by limited proteolysis.

Authors:  Angelo Fontana; Patrizia Polverino de Laureto; Barbara Spolaore; Erica Frare; Paola Picotti; Marcello Zambonin
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

4.  Predicting the adsorption of proteins by aluminium-containing adjuvants.

Authors:  S J Seeber; J L White; S L Hem
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

5.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

7.  Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens.

Authors:  LaToya S Jones; Laura J Peek; Jonathan Power; Aaron Markham; Brian Yazzie; C Russell Middaugh
Journal:  J Biol Chem       Date:  2005-01-31       Impact factor: 5.157

8.  Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity.

Authors:  Martinus A H Capelle; Peter Brügger; Tudor Arvinte
Journal:  Vaccine       Date:  2005-02-25       Impact factor: 3.641

9.  Anthrax toxin complexes: heptameric protective antigen can bind lethal factor and edema factor simultaneously.

Authors:  Ruth-Anne L Pimental; Kenneth A Christensen; Bryan A Krantz; R John Collier
Journal:  Biochem Biophys Res Commun       Date:  2004-09-10       Impact factor: 3.575

10.  Conformational fluctuations in anthrax protective antigen: a possible role of calcium in the folding pathway of the protein.

Authors:  Pradeep K Gupta; Harish Chandra; Reetika Gaur; Raj K Kurupati; Shantanu Chowdhury; Vibha Tandon; Yogendra Singh; Kapil Maithal
Journal:  FEBS Lett       Date:  2003-11-20       Impact factor: 4.124

View more
  9 in total

1.  Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.

Authors:  Weiqiang Cheng; Elena Curti; Wanderson C Rezende; Clifford Kwityn; Bin Zhan; Portia Gillespie; Jordan Plieskatt; Sangeeta B Joshi; David B Volkin; Peter J Hotez; C Russell Middaugh; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

2.  Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Authors:  Leslie Wagner; Anita Verma; Bruce D Meade; Karine Reiter; David L Narum; Rebecca A Brady; Stephen F Little; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

Review 3.  Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen.

Authors:  Mohammed Ali Dahhas; Mohammad A Alsenaidy
Journal:  Saudi Pharm J       Date:  2022-02-25       Impact factor: 4.562

4.  Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Authors:  Allan Watkinson; Andrei Soliakov; Ashok Ganesan; Karie Hirst; Chris Lebutt; Kelly Fleetwood; Peter C Fusco; Thomas R Fuerst; Jeremy H Lakey
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

5.  Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.

Authors:  Mette Hamborg; Lene Jorgensen; Anders Riber Bojsen; Dennis Christensen; Camilla Foged
Journal:  Pharm Res       Date:  2012-09-06       Impact factor: 4.200

Review 6.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

7.  Helix N-Cap Residues Drive the Acid Unfolding That Is Essential in the Action of the Toxin Colicin A.

Authors:  Yan Huang; Andrei Soliakov; Anton P Le Brun; Colin Macdonald; Christopher L Johnson; Alexandra S Solovyova; Helen Waller; Geoffrey R Moore; Jeremy H Lakey
Journal:  Biochemistry       Date:  2019-11-13       Impact factor: 3.162

Review 8.  Vaccine delivery using nanoparticles.

Authors:  Anthony E Gregory; Richard Titball; Diane Williamson
Journal:  Front Cell Infect Microbiol       Date:  2013-03-25       Impact factor: 5.293

9.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.